Zymeworks (ZYME) Change in Receivables (2021 - 2026)
Zymeworks' (ZYME) quarterly Change in Receivables came in at $36000.0 in Q1 2026, up 100.12% year-on-year from $17989.6 in Q1 2025, and up 100.15% quarter-over-quarter from -$24.7 million in Q4 2025.
Zymeworks (ZYME) Change in Receivables (2021 - 2026) Analysis & Trends
Zymeworks has disclosed Change in Receivables across 6 years of filings, most recently posting $36000.0 for Q1 2026.
- Change in Receivables for Q1 2026 came in at $36000.0, up 100.12% year-over-year; the trailing twelve-month figure through Mar 2026 was -$19.9 million (down 215.19% YoY), and the FY2025 annual result was -$51.2 million, down 240.82% from the prior year.
- Change in Receivables came in at $36000.0 for Q1 2026 at Zymeworks, up from -$24.7 million in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $33.5 million in Q1 2023 to a low of -$47.8 million in Q4 2023.
- The 5-year median for Change in Receivables is $36000.0 (2026), against an average of -$659882.4.
- Peak annual rise in Change in Receivables reached 697.92% in 2023, while the deepest fall reached 11886.09% in 2023.
- Zymeworks' Change in Receivables stood at $26.7 million in 2022, then slumped by 279.2% to -$47.8 million in 2023, then jumped by 166.18% to $31.6 million in 2024, then plunged by 178.13% to -$24.7 million in 2025, then jumped by 100.15% to $36000.0 in 2026.
- The last three Change in Receivables figures came in at $36000.0 (Q1 2026), -$24.7 million (Q4 2025), and $26.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 22,529.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -39.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -4.08 Mn |
| 10 | Zymeworks | 1.73 Bn | 1.36 Bn | - | 36,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 36,000.00 |
| Mar 31, 2026 | 36,000.00 |
| Dec 31, 2025 | -24.71 Mn |
| Dec 31, 2025 | -24.71 Mn |
| Sep 30, 2025 | 26.72 Mn |
| Sep 30, 2025 | 26.72 Mn |
| Jun 30, 2025 | -21.99 Mn |
| Jun 30, 2025 | -21.99 Mn |
| Mar 31, 2025 | -31.22 Mn |
| Mar 31, 2025 | -31.22 Mn |
| Dec 31, 2024 | 31.63 Mn |
| Dec 31, 2024 | 31.63 Mn |
| Sep 30, 2024 | -7.88 Mn |
| Sep 30, 2024 | -7.88 Mn |
| Jun 30, 2024 | 1.14 Mn |
| Jun 30, 2024 | 1.14 Mn |
| Mar 31, 2024 | 11.47 Mn |
| Mar 31, 2024 | 11.47 Mn |
| Dec 31, 2023 | -47.80 Mn |
| Dec 31, 2023 | -47.80 Mn |